Results 171 to 180 of about 27,235 (300)

Bispecific antibodies combined with chemotherapy in solid tumor treatment, the path forward? [PDF]

Front Immunol
Yan Y, Yuan J, Peng Y, Zhou C, Liu X, Sun L, Song Q.   +6 more
europepmc   +1 more source

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma [PDF]

, 2009
Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien‐Hsing Chang   +4 more
openalex   +1 more source

Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis

Haemophilia, EarlyView.
ABSTRACT Background Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII‐equivalent activity (FVIIIeq) of emicizumab remains unknown. Objectives To estimate FVIIIeq of emicizumab using global assays of haemostasis.
Daniel Kraemmer, Cihan Ay, Judit Rejtő, Georg Heinze, Peter Quehenberger, Ingrid Pabinger, Oliver Königsbrügge   +6 more
wiley   +1 more source

Incidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies. [PDF]

J Korean Med Sci
Park T, Jang S, Koh Y, Shin DY, Yoon SS, Lee CM, Jo HJ, Choe PG, Park WB, Kim NJ, Kang CK, Byun JM.   +11 more
europepmc   +1 more source

Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy [PDF]

, 2010
Robert M. Sharkey, Edmund A. Rossi, William J. McBride, Chien‐Hsing Chang, David M. Goldenberg   +4 more
openalex   +1 more source

Platforms for studying cell–cell recognition by immune cells

Immunology &Cell Biology, EarlyView.
This review compares different platforms for studying how immune cells integrate signals from co‐signaling receptor‐ligand interactions at cell–cell interfaces. By understanding the strengths and weaknesses of each platform, including which factors can be controlled by the user, immunologists can identify the most appropriate platform to address their ...
Jordan Kramer, P Anton van der Merwe, Omer Dushek   +2 more
wiley   +1 more source

Characteristics of second primary malignancies following bispecific antibodies therapy. [PDF]

J Immunother Cancer
Liang X, Luo B, Lin B, Liu D, Guo J, Lu W, Tian S, Cai Z, Zhou X, Jin Z, Li T, Chen K, Zhou H, Wang L.   +13 more
europepmc   +1 more source

A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells [PDF]

, 2010
Edmund A. Rossi, Diane L. Rossi, Rhona Stein, David M. Goldenberg, Chien‐Hsing Chang   +4 more
openalex   +1 more source

Impact of cellular composition and T‐cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T‐cells

Transfusion, EarlyView.
Abstract Background Apheresis procedure of autologous lymphocytes competent for proliferation and expansion is a crucial step in the production of chimeric antigen receptor (CAR) T‐cells. Previous therapies or disease status prior to collection may negatively impact the collections.
Vladan Vučinić, Theresa Tumewu, Mandy Brückner, Janine Kirchberg, Madlen Jentzsch, Raymund Buhmann, Yvonne Remane, Sandra Hoffmann, Florian Ramdohr, Maximilian Merz, Klaus H. Metzeler, Sebastian Schwind, Carmen Herling, Simon M. Krauß, Marco Herling, Georg‐Nikolaus Franke, Nora Grieb, Georg Stachel, Martin Janz, Olaf Penack, Lars Bullinger, Ulrich Keller, Michael Cross, Reinhard Henschler, Enrica Bach, Uwe Platzbecker   +25 more
wiley   +1 more source

Bispecific Antibodies for Lymphoid Malignancy Treatment. [PDF]

Cancers (Basel)
Bisio M, Legato L, Fasano F, Benevolo Savelli C, Boccomini C, Nicolosi M, Santambrogio E, Freilone R, Novo M, Botto B.   +9 more
europepmc   +1 more source